Treatment of Ccm2ECKO mice with CD5-2 conferred a significant reduction (Fig 3B) with around 60% inhibition in both total CCM lesion volume and on the size of the large lesions (Fig 3Ci-iv). The gene discussed is CD52; the disease is cerebral cavernous malformation.